1887

Abstract

Delay of active antimicrobial therapy in haematological patients with Gram-negative bacilli bacteraemia during profound neutropenia exposes them to increased morbidity and mortality. The digestive tract is the main source of enterobacteria causing bacteraemia in these patients. We thus evaluated the usefulness of broad-spectrum beta-lactam resistant enterobacteria (BSBL-RE) faecal shedding assessment in forecasting the susceptibility to BSBLs of the strains isolated from blood cultures. From 2002 to 2011, neutropenic haematological patients with bacteraemia caused by enterobacteria who had a stool culture during the previous 7 days were retrospectively included. BSBL-RE intestinal carriers were compared with non-carriers in terms of clinical and microbiological criteria. One hundred and four patients were included and 16 of them (15.4 %) were BSBL-RE carriers. Multivariate analysis showed that BSBL-RE carriage was independently associated with BSBL-RE identified in blood cultures ( < 0.001) and the use of carbapenems as empirical treatment of the bacteraemia ( = 0.008). Sensitivity, specificity, and the positive and negative predictive values of the test were 80 %, 91 %, 50 % and 98 %, respectively. Among the carriers, those with the highest level of BSBL-RE carriage were also those with the highest risk of bacteraemia due to BSBL-RE ( < 0.001). Close monitoring of BSBL-RE intestinal carriage may help to choose the most appropriate initial antimicrobial treatment for neutropenic haematological patients with bacteraemia.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.000078
2015-07-01
2020-06-05
Loading full text...

Full text loading...

/deliver/fulltext/jmm/64/7/676.html?itemId=/content/journal/jmm/10.1099/jmm.0.000078&mimeType=html&fmt=ahah

References

  1. Arnan M., Gudiol C., Calatayud L., Liñares J., Dominguez M.A., Batlle M., Ribera J.M., Carratalà J., Gudiol F. 2011; Risk factors for, and clinical relevance of, faecal extended-spectrum β-lactamase producing Escherichia coli (ESBL-EC) carriage in neutropenic patients with haematological malignancies. Eur J Clin Microbiol Infect Dis 30:355–360 [CrossRef][PubMed]
    [Google Scholar]
  2. Averbuch D., Orasch C., Cordonnier C., Livermore D.M., Mikulska M., Viscoli C., Gyssens I.C., Kern W.V., Klyasova G., other authors. 2013; European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia. Haematologica 98:1826–1835 [CrossRef]
    [Google Scholar]
  3. Bow E.J. 2005; Management of the febrile neutropenic cancer patient: lessons from 40 years of study. Clin Microbiol Infect 11:(Suppl 5)24–29 [CrossRef][PubMed]
    [Google Scholar]
  4. Bow E.J. 2013; There should be no ESKAPE for febrile neutropenic cancer patients: the dearth of effective antibacterial drugs threatens anticancer efficacy. J Antimicrob Chemother 68:492–495 [CrossRef][PubMed]
    [Google Scholar]
  5. Cantón R., Akóva M., Carmeli Y., Giske C.G., Glupczynski Y., Gniadkowski M., Livermore D.M., Miriagou V., Naas T., other authors. 2012; Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe. Clin Microbiol Infect 18:413–431 [CrossRef][PubMed]
    [Google Scholar]
  6. Cornejo-Juárez P., Pérez-Jiménez C., Silva-Sánchez J., Velázquez-Acosta C., González-Lara F., Reyna-Flores F., Sánchez-Pérez A., Volkow-Fernández P. 2012; Molecular analysis and risk factors for Escherichia coli producing extended-spectrum β-lactamase bloodstream infection in hematological malignancies. PLoS One 7:e35780 [CrossRef][PubMed]
    [Google Scholar]
  7. Freifeld A.G., Bow E.J., Sepkowitz K.A., Boeckh M.J., Ito J.I., Mullen C.A., Raad I.I. II, Rolston K.V., Young J.A., other authors. 2011; Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. Clin Infect Dis 52:427–431 [CrossRef][PubMed]
    [Google Scholar]
  8. Friedman C.R., Whitney C.G. 2008; It's time for a change in practice: reducing antibiotic use can alter antibiotic resistance. J Infect Dis 197:1082–1083 [CrossRef][PubMed]
    [Google Scholar]
  9. Gudiol C., Calatayud L., Garcia-Vidal C., Lora-Tamayo J., Cisnal M., Duarte R., Arnan M., Marin M., Carratalà J., Gudiol F. 2010; Bacteraemia due to extended-spectrum beta-lactamase-producing Escherichia coli (ESBL-EC) in cancer patients: clinical features, risk factors, molecular epidemiology and outcome. J Antimicrob Chemother 65:333–341 [CrossRef][PubMed]
    [Google Scholar]
  10. Kim S.H., Kwon J.C., Choi S.M., Lee D.G., Park S.H., Choi J.H., Yoo J.H., Cho B.S., Eom K.S., other authors. 2013; Escherichia coli and Klebsiella pneumoniae bacteremia in patients with neutropenic fever: factors associated with extended-spectrum β-lactamase production and its impact on outcome. Ann Hematol 92:533–541 [CrossRef][PubMed]
    [Google Scholar]
  11. Kwon J.C., Kim S.H., Choi J.K., Cho S.Y., Park Y.J., Park S.H., Choi S.M., Lee D.G., Choi J.H., Yoo J.H. 2013; Epidemiology and clinical features of bloodstream infections in hematology wards: one year experience at the catholic blood and marrow transplantation center. Infect Chemother 45:51–61 [CrossRef][PubMed]
    [Google Scholar]
  12. Liss B.J., Vehreschild J.J., Cornely O.A., Hallek M., Fätkenheuer G., Wisplinghoff H., Seifert H., Vehreschild M.J. 2012; Intestinal colonisation and blood stream infections due to vancomycin-resistant enterococci (VRE) and extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBLE) in patients with haematological and oncological malignancies. Infection 40:613–619 [CrossRef][PubMed]
    [Google Scholar]
  13. Micol J.B., Chahine C., Woerther P.L., Ghez D., Netzer F., Dufour C., Merad M., Blot F., Chachaty E., other authors. 2014; Discontinuation of empirical antibiotic therapy in neutropenic acute myeloid leukaemia patients with fever of unknown origin: is it ethical?. Clin Microbiol Infect 20:O453–O455[PubMed] [CrossRef]
    [Google Scholar]
  14. Ortega M., Marco F., Soriano A., Almela M., Martínez J.A., Muñoz A., Mensa J. 2009; Analysis of 4758 Escherichia coli bacteraemia episodes: predictive factors for isolation of an antibiotic-resistant strain and their impact on the outcome. J Antimicrob Chemother 63:568–574 [CrossRef][PubMed]
    [Google Scholar]
  15. Pizzo P.A., Robichaud K.J., Gill F.A., Witebsky F.G. 1982; Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 72:101–111 [CrossRef][PubMed]
    [Google Scholar]
  16. Tancrède C.H., Andremont A.O. 1985; Bacterial translocation and Gram-negative bacteremia in patients with hematological malignancies. J Infect Dis 152:99–103 [CrossRef][PubMed]
    [Google Scholar]
  17. Tumbarello M., Sali M., Trecarichi E.M., Leone F., Rossi M., Fiori B., De Pascale G., D'Inzeo T., Sanguinetti M. 2008; Bloodstream infections caused by extended-spectrum-beta-lactamase-producing Escherichia coli: risk factors for inadequate initial antimicrobial therapy. Antimicrob Agents Chemother 52:3244–3252 [CrossRef][PubMed]
    [Google Scholar]
  18. Tumbarello M., Trecarichi E.M., Bassetti M., De Rosa F.G., Spanu T., Di Meco E., Losito A.R., Parisini A., Pagani N., Cauda R. 2011; Identifying patients harboring extended-spectrum-beta-lactamase-producing Enterobacteriaceae on hospital admission: derivation and validation of a scoring system. Antimicrob Agents Chemother 55:3485–3490 [CrossRef][PubMed]
    [Google Scholar]
  19. Walsh T.R., Toleman M.A. 2012; The emergence of pan-resistant Gram-negative pathogens merits a rapid global political response. J Antimicrob Chemother 67:1–3 [CrossRef][PubMed]
    [Google Scholar]
  20. Woerther P.L., Burdet C., Chachaty E., Andremont A. 2013; Trends in human fecal carriage of extended-spectrum β-lactamases in the community: toward the globalization of CTX-M. Clin Microbiol Rev 26:744–758 [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.000078
Loading
/content/journal/jmm/10.1099/jmm.0.000078
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error